OxiProteomics was conceived after several years of cutting edge research in the early molecular events related to ageing, age related diseases, and oxidative stress. We deliver proven science services to dermo-cosmetic and food industries to support marketing claims. We also offer environmental quality bio-monitoring solutions to promote sustainable development.We engineered an optimized process of targeted and untargeted proteomics analyses adapted to different biological matrices which allows us to collect large sets of results and think about data interactively, in real-time and dynamically. That’s how new ideas come up, and drive us to find novel applications in different fields.

The Cosmetic Valley is an association wishing to promote synergies in short circuits and jointly display the values ​​of the cosmetics Made in France brand internationally. Created in 1994 and labeled as a competitiveness cluster, the Cosmetic Valley is mandated by government since 2014 to coordinate the French perfume and cosmetics national sector. The French cosmetic perfume industry brings together 3,200 companies, 80% of which are SMEs, employing 250,000 professionals. It invests more than 650 million euros in R&D each year. It constitutes a real industrial fabric between large groups and SMEs, public and private players, laboratories, universities and training establishments. In France, it integrates all the links in the sector, from the cultivation of medicinal or aromatic plants to the packaging and distribution of finished skincare, make-up, perfume and hygiene products.Cosmetic Valley is the first cluster dedicated to the perfumery-cosmetics industry to have been created in the world. Its model is now spread all over the world and Cosmetic Valley thus benefits from a global network of clusters connected to the service of the development of innovation and international partnerships in the field of cosmetic perfumery.

OncoDiag is a French biotech start-up specialised in early cancer diagnostics. Our innovative medical devices intend to redefine cancer care with non-invasive tests based on personalized biomarker analyses. Introducing:URODIAG®: Transforming bladder cancer monitoring with a urine test, minimizing cystoscopy needs. By detecting recurrences at an early stage, even in low/intermediate grade NMI bladder cancer cases, Urodiag lightens the patient's load and offers cost-effective benefits. The test is now marketed in France and Europe.PROSTADIAG®: This tests perecisely differentiates indolent from aggressive prostate cancers, guiding informed medical choices. Final clinical validation underway.COLODIAG® : Innovative blood test for colorectal cancer screening, endorsed for simplicity and potential to reduce cancer prevalence. . Initial clinical validation ongoing.

Postdoctoral scientist at the Biological Adaptation & Aging UMR 8256 (INSERM, CNRS, Sorbonne University). Aging is a progressive deterioration of cellular functions resulting in disease and death, but its molecular causes are not completely understood. Increased protein oxidative damage has been reported during aging in different organisms. The central hypothesis underlying my research states that protein damage is a major cause of cellular dysfunction during aging. Mechanistically, such damage would lead to critical alterations in the structure-function of key cellular proteins. In the recent years I have been involved in studies evidencing that the oxi-proteome (the sub-set of the cellular proteome targeted by carbonylation) during aging and age-related diseases is composed only by a restricted group of proteins, indicating that not all proteins have the same susceptibility for oxidation and propensity to accumulate at oxidized forms. Common processes such as increased oxidative stress, accumulation of protein damage and general metabolic dysfunction are suggested to be causally involved in aging. However, these processes have been mostly seen as independent events. A key question to approach is whether this deregulation is driven principally by oxidative damage of key enzymes. My research was aimed at defining the causal role of oxidized proteins in the human ageing process.

As a graduate student (2006-2008) in Pr. Bernardino Ghetti´s lab (Indiana University, USA) my focus of research was the molecular characterization of a mutant ferritin that causes Hereditary Ferritinopathy, a neurodegenerative disease characterized by the presence of ferritin containing inclusion bodies and iron accumulation in the CNS. We found that the mutation induced conformational changes in the mutant ferritin leading to iron mismanagement and importantly iron-induced protein aggregation, consistent to what observed in patients carrying the mutation (J Biol Chem, 2008). Furthermore, we also solved its structure using X-ray crystallography, which support the structural basis of iron mismanagement observed (J. Biol. Chem, 2010). Importantly, we also identified oxidative post-translational modifications in the mutated protein and a free radical-mediated cleavage of the polypeptide chain, due to iron-catalyzed oxidation as a consequence of iron mishandling (FRB&M, 2012).